- Home
- Results news
- Gayatri BioOrganics
- Q2 FY27 results
Gayatri BioOrganics Q2 FY27 results: net profit ₹0.05 crore vs ₹0.21 crore loss
Gayatri BioOrganics Ltd reported standalone revenue of ₹3.54 crore and a net profit of ₹0.05 crore for Q2 FY27, versus no revenue and a net loss of ₹0.21 crore in Q2 FY26. EBITDA was ₹0.16 crore at a 4.6% margin, while basic EPS was ₹0.01. The company’s name was changed to Ananth BioOrganics Limited with effect from 16 October 2026.
Key points
- Standalone Q2 FY27 revenue was ₹3.54 crore, up ₹3.54 crore from Q2 FY26.
- EBITDA was ₹0.16 crore in Q2 FY27, compared with a loss of ₹0.13 crore in Q2 FY26.
- The EBITDA margin was 4.6% in Q2 FY27, up 4.4 percentage points from Q1 FY27.
- Q2 FY27 net profit was ₹0.05 crore and basic EPS was ₹0.01, versus a net loss of ₹0.21 crore and EPS of ₹0.03 in Q2 FY26.
- In H1 FY27, revenue was ₹5.87 crore and net loss was ₹0.05 crore, compared with no revenue and a net loss of ₹0.47 crore in H1 FY26.
How did Gayatri BioOrganics perform in Q2 FY27?
Gayatri BioOrganics reported standalone revenue of ₹3.54 crore in Q2 FY27, up ₹3.54 crore from Q2 FY26 and ₹1.20 crore, or 51.3%, from Q1 FY27. EBITDA was ₹0.16 crore with a 4.6% margin, compared with a loss of ₹0.13 crore in Q2 FY26 and EBITDA of ₹0.01 crore at a 0.2% margin in Q1 FY27.
The company reported profit before tax and net profit of ₹0.05 crore in Q2 FY27, compared with a net loss of ₹0.21 crore in Q2 FY26 and ₹0.10 crore in Q1 FY27. Basic EPS was ₹0.01, against ₹0.03 in Q2 FY26 and ₹0.01 in Q1 FY27. The results were standalone; no consolidated figures were given.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3.54 | 2.34 | 0 | +51.3% | |
| Other income | 0 | 0 | 0 | ||
| Total expenses | 3.49 | 2.44 | 0.21 | +1561.9% | +43.0% |
| EBITDA | 0.16 | 0.01 | −0.13 | turned to profit | +1500.0% |
| EBITDA margin | 4.6% | 0.2% | +4.4 pp | ||
| Profit before tax | 0.05 | −0.10 | −0.21 | turned to profit | turned to profit |
| Tax | 0 | 0 | 0 | ||
| Net profit | 0.05 | −0.10 | −0.21 | turned to profit | turned to profit |
| EPS (₹) | 0.01 | −0.01 | −0.03 | turned to profit | turned to profit |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Gayatri BioOrganics' costs and profit?
Total expenses increased by ₹3.28 crore from Q2 FY26 to ₹3.49 crore in Q2 FY27. Employee cost was ₹0.02 crore, up ₹0.01 crore or 100.0%, while finance costs were ₹0.11 crore, up ₹0.02 crore or 22.2%. Other expenses were ₹0.09 crore, down ₹0.02 crore or 18.2%.
Other income was unchanged at no exceptional item. There was no exceptional item and no tax expense in Q2 FY27. Against Q1 FY27, total expenses rose ₹1.05 crore or 43.0%, while other expenses fell ₹0.07 crore or 43.8%; employee cost and finance costs were unchanged.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 0 | 0 | 0 | |
| Employee cost | 0.02 | 0.01 | +0.01 | +100.0% |
| Finance costs | 0.11 | 0.09 | +0.02 | +22.2% |
| Depreciation | 0 | 0 | 0 | |
| Other expenses | 0.09 | 0.11 | −0.02 | −18.2% |
| Total expenses | 3.49 | 0.21 | +3.28 | +1561.9% |
| Other income | 0 | 0 | 0 | |
| Tax | 0 | 0 | 0 |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
For H1 FY27, standalone revenue and total income were ₹5.87 crore, compared with no revenue in H1 FY26. Loss before tax and net loss narrowed to ₹0.05 crore from ₹0.47 crore, an improvement of ₹0.42 crore.
Basic EPS in H1 FY27 was ₹0.01 compared with ₹0.06 in H1 FY26, an improvement of ₹0.05. The company’s results were reviewed by the Audit Committee and taken on record by the Board on 5 November 2026.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 5.87 | 0 | |
| Profit before tax | −0.05 | −0.47 | |
| Net profit | −0.05 | −0.47 | |
| EPS (₹) | −0.01 | −0.06 |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 30 September 2026, total assets were ₹2.04 crore, up from ₹1.72 crore at 31 March 2026. Total equity remained negative at ₹37.06 crore, compared with negative ₹37.01 crore, while borrowings rose to ₹37.54 crore from ₹36.98 crore and cash was ₹0.03 crore versus ₹0.02 crore.
Trade receivables increased to ₹0.59 crore from ₹0.25 crore, and trade payables rose to ₹0.49 crore from no amount. H1 FY27 net cash used in operating activities was ₹0.56 crore, compared with ₹0.38 crore in H1 FY26, while financing cash flow was ₹0.57 crore versus ₹0.40 crore.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 2.04 | 1.72 |
| Total equity | −37.06 | −37.01 |
| Borrowings | 37.54 | 36.98 |
| Cash and equivalents | 0.03 | 0.02 |
| Inventories | 0 | 0 |
| Trade receivables | 0.59 | 0.25 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | −0.56 | −0.38 |
| Cash from investing | 0 | 0 |
| Cash from financing | 0.57 | 0.40 |
| Capital expenditure | 0 | 0 |
Source: Company's results filing (XBRL).
How has Gayatri BioOrganics done over the last 8 quarters?
Revenue reached ₹3.54 crore in Q2 FY27 after ₹2.34 crore in Q1 FY27, while the preceding six quarters reported no revenue. Net profit moved from a loss of ₹0.10 crore in Q1 FY27 to a profit of ₹0.05 crore in Q2 FY27, after losses in each quarter from Q3 FY25 through Q4 FY26.
The EBITDA margin increased from 0.2% in Q1 FY27 to 4.6% in Q2 FY27. Across the available quarterly series, revenue peaked at ₹3.54 crore and net profit peaked at ₹0.05 crore in Q2 FY27; the latest quarter also marked the move from loss to profit.
How did other Commodity Chemicals companies do?
Among 27 other Commodity Chemicals companies that filed this quarter, the median revenue growth was 25.3%. The company’s revenue growth was higher than the median shown for this peer group.
Of the 32 peer companies whose profit was compared, 25 reported higher profit. The filing data does not provide the number of peers that grew revenue slower or faster than Gayatri BioOrganics.
| Gayatri BioOrganics revenue growth (YoY) | not comparable |
|---|---|
| Median of 27 other Commodity Chemicals companies | +25.3% |
| Companies whose net profit rose | 25 of 32 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Gayatri BioOrganics' revenue in Q2 FY27?
Revenue from operations was ₹3.54 crore, against ₹0 crore in Q2 FY26 (standalone).
Did Gayatri BioOrganics make a profit in Q2 FY27?
Yes. Net profit was ₹0.05 crore, against a net loss of ₹0.21 crore in Q2 FY26.
What was Gayatri BioOrganics' EPS in Q2 FY27?
Basic earnings per share were ₹0.01, against a loss of ₹0.03 in Q2 FY26.
When did Gayatri BioOrganics announce its Q2 FY27 results?
On 5 November 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Meeting To Be Held On 05.11.2026 (BSE, 2 November 2026) · PDF
- Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2026 (BSE, 5 November 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.